Board and Management

Cinclus Pharma AB

Trädgårdsgatan 54

431 35 Mölndal

SWEDEN

info@cincluspharma.com

Copyright © All Rights Reserved

Kjell Andersson, CEO

+46 733 337 906


Peter Unge, CMO

+46 705 763 780

Board and management

Management team

Kjell Andersson, PhD

Chief Executive Officer and Co-Founder

  • Ph.D. Pharmacologist with 30 years’ of experience from Astra/AstraZeneca

  • Preclinical project leader for Losec, the first PPI on the market

  • Preclinical project leader for Nexium including clinical, marketing

    and regulatory support

  • Discovery project leader on the P-CAB program bringing linaprazan through the phase II studies

Peter Unge, MD, PhD

Chief Medical Officer, Board Director and Co-Founder

  • MD. Ph.D. Gastroenterologist with 25 years’ of Healthcare experience
  • Developed the first modern H. pylori eradication therapy principles  
  • Supported sNDAs and medical affairs at AstraZeneca for 13 years
  • Novartis HQ in Basel, Switzerland for 12 years in drug development
  • Assigned as VP and Head of the Scientific Office, SOP and Training compliance Offices

Board of Directors

Wenche Rolfsen, PhD, Professor

Chair of the Board 

  • Ph.D in Pharmacology. More than 30 years in drug discovery and development from Pharmacia and Quintiles

  • Over the last 15 years, she has been on the Board of many life Science companies, private, governmentally owned and publicly listed in Norway, UK and Sweden

  • Currently active as Chairman of Index Pharmaceuticals and Sarsia Seed and member of the Board of Swedish Match, Recipharm, BioArctic and Moberg Pharma

Lennart Hansson, PhD 

Board Director and Co-Founder

  • Ph.D. in Genetics. More than 25 years’ experience in senior executive positions for R&D and business development in pharmaceutical- and biotech industry, including KabiGen, Symbicom, AstraZeneca, Biovitrum and Arexis
  • Has filed more than 20 patent applications and published more than 50 scientific papers
  • For the last 9 years he has been responsible for venture capital investments in Life Science
  • Served as Board director in more than 25 life science companies

Torbjörn Koivisto

Board Director 

  • More than 10 years’ experience as a business lawyer from law firms Mannheimer Swartling, Lindahl and Bird & Bird
  • Since 2006 working for his own company IARU, advising clients within the life sciences industry on matters of commercial and corporate law
  • He is currently active as a member of the Board of Xspray Pharma and Hemcheck Sweden

Peter Unge, MD, PhD

Board Director, Chief Medical Officer and Co-Founder

  • MD. Ph.D. Gastroenterologist with 25 years’ of Healthcare experience
  • Developed the first modern H. pylori eradication therapy principles
  • Supported sNDAs and medical affairs at AstraZeneca for 13 years
  • Novartis HQ in Basel, Switzerland for 12 years in drug development
  • Assigned as VP and Head of the Scientific Office, SOP and Training compliance Offices

Anders Öhberg, M.Sc.

Board Director

  • More than 12 years experience from drug development and medical affairs within the pharmaceutical industry

  • He has held a broad a spectrum of positions within clinical development, pharmacovigilance, quality assurance and medical affairs at Pfizer, Ipsen, Shire and Novartis

  • Currently heading the Nordic medical affairs business for gene therapy at Novartis within rare ophthalmology. Anders holds a
    master’s degree in medical sciences and clinical drug development from Uppsala University